Gazi University
gazi.edu.trTotal trials
508
Active
85
Phase 3
0
Total enrollment
47,075
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Pembrolizumab | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | — | 1 | |
| Ipilimumab | — | — | — | — | — | 1 |
Next readouts
- 2027-08
Top conditions
- Multiple Sclerosis24
- Cerebral Palsy14
- Parkinson Disease13
- Healthy9
- Anxiety9
- Periodontitis8
- Gingival Recession6
- Stroke6
Frequently asked questions about Gazi University
- How many clinical trials does Gazi University have on ClinicalTrials.gov?
- Gazi University is listed as the lead sponsor on 508 clinical trials in ClinicalTrials.gov, 85 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Gazi University's trials are in Phase 3?
- 0 of Gazi University's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Gazi University focus on?
- Gazi University's most-studied conditions on ClinicalTrials.gov are Multiple Sclerosis, Cerebral Palsy, Parkinson Disease, Healthy, Anxiety.
- When are Gazi University's next clinical trial readouts?
- Gazi University has 1 upcoming primary-completion readout tracked here; the soonest is “Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)”, expected around 2027-08.